| I N T R O D U C T I O N
Sinonasal adenoid cystic carcinoma (ACC) is a rare malignancy characterized by an insidious growth pattern and a tendency for perineural spread along major and minor nerves, resulting in invasion of the skull base as well as intracranial extension.
1,2 Therefore, many patients present with advanced disease with involvement of critical structures making treatment difficult and potentially morbid. 2 Local recurrence and distant metastasis can occur decades after definitive treatment making some consider ACC to be incurable. 1, [3] [4] [5] Infection by high-risk human papillomavirus (HPV) has been identified as a causative agent for squamous cell carcinoma (SCC), particularly in the oropharynx. 6 Recently, it has been demonstrated that the incidence is increasing, with estimates that up to 60%-70% of oropharyngeal SCCs are HPV-related. 7, 8 HPV-related SCC of the oropharynx is associated with a 58% reduction in the risk of death when compared with patients with HPV-negative tumors. 9 Because of the favorable prognosis of patients with HPV-related oropharyngeal cancers, there are numerous trials investigating new treatment strategies for HPVrelated cancer, including the use of alternative chemotherapy agents, induction chemotherapy, and using lower doses of radiation. 10, 11 The presence of high-risk HPV as a potential causative agent in sinonasal cancer is also being investigated. A recent series suggests that up to 21% of sinonasal carcinomas are HPV-related. 12, 13 Moreover, patients with sinonasal SCC associated with HPV were found to have improved progression-free survival and overall survival (OS) when compared with their HPV-negative counterparts. 13 ACC of the cervix has previously been found to be associated with high risk HPV. 14, 15 A limited number of studies have investigated the association of high-risk HPV and p16 expression, which is a surrogate marker for the presence of HPV, with sinonasal ACC. 12, 16, 17 One study by Bishop et al 16 identified and characterized an HPV-positive sinonasal carcinoma with adenoid cystic-like features. In that study, 8 cases, all localized to the sinonasal tract, were found to resemble ACC histologically, and were positive for HPV with strong and diffuse p16 immunoreactivity. The purpose of this study was to review our long-term outcomes of patients with sinonasal ACC, including treatment response, patterns of recurrence, and treatment toxicity. In addition, we sought to further clarify the association of HPV in sinonasal ACC.
| MATERIALS A ND METHODS

| Patient selection
After approval from the institutional review board at the Ohio State University James Cancer Hospital, we identified 44 patients with biopsy-confirmed sinonasal ACC who were consecutively evaluated for radiotherapy (RT) between 1998 and 2013 using electronic treatment records maintained by the Department of Radiation Oncology. After excluding patients <18 years old and those not treated definitively, 23 patients were left for analysis. Data for the cohort were collected through electronic and paper record review.
| Treatment
For each patient, a full medical history and physical examination was Foster City, CA) as previously described. 18, 19 The primers and probe for amplification were designed to target on the E6 and/or E7 region and were synthesized by Integrated DNA Technologies (Coralville, IA).
| Laboratory analysis
Probes were labeled with 6-carboxy-fluorescein at the 5 0 end and with Black Hole Quencher-1 at the 3 0 end. The sequences for primers and probes have been previously published. 20 Standard curves for amplification reactions were generated in duplicate by using a 5-fold dilution series (from 250 000 to 3.2 copies) of pUC57 vector The final dissociation curve analysis used the default program setting.
An estimate of cell numbers in each of the samples was tested by
TaqMan real-time PCR targeting on a single-copy human gene on chromosome 7, human endogenous retrovirus 3 (ERV3). 21 The 58-bp ERV3 fragment was amplified for 17 samples and the reaction conditions were as previously published. 18 Briefly, 2 lL of purified tumor tissue DNA was analyzed. A standard curve was generated in duplicate from a 5-fold dilution series (from 150 000 to 1.92 cells) of a diploid human cell line, CCD-18LU (ATCC, Manassas, VA). Results were reported as the number of human diploid genome equivalents of purified genomic DNA from tumor samples that were evaluated for HPV type(s) DNA by quantitative PCR.
| p16 immunohistochemistry
Samples were also evaluated using IHC for expression of a surrogate biomarker of HPV E7 oncoprotein function, the cdk inhibitor p16. 70% of the tumor cells, as previously described. 20 
| Statistical analysis
Local failure was defined as the time from the final treatment date to the date of recurrence in the treatment field based on biopsy or imaging. Disease-free survival (DFS) was defined as the time from the final treatment date to the date of disease recurrence either locally or distantly. OS was defined as the time from the date of diagnosis until the date of death. Survival curves were estimated using the method of Kaplan-Meier. The log-rank test was used to compare between the survival curves. All statistical tests were 2-sided and a P value of < .05 was considered statistically significant. All statistical analyses were performed using SAS version 9.4 (SAS, Cary, NC).
| R E S U LTS
| Patient characteristics and survival analysis
Patient and tumor characteristics are summarized in Table 1 . The median age at presentation was 55 years (range 20-73 years) with the majority of patients being men (65%). The most common presenting symptoms included pain, epistaxis, nasal obstruction, and headaches.
Twenty patients (87%) were evaluated for a primary diagnosis, whereas 3 patients (13%) presented with recurrent disease. The most common primary tumor sites were the maxillary sinus (52%) and nasal cavity (35%) with the majority of patients presenting with clinical T4 disease (57%). All patients were clinically without evidence of distant metastasis on preoperative workup.
All patients were treated with primary surgical resection. Total maxillectomy was performed in 9 patients (39%) and partial maxillectomy was performed in 9 patients (39%). Craniofacial resection was required in 4 patients (17%), whereas endoscopic endonasal resection was completed in 3 patients (13% 
| Human papillomavirus DNA detection and p16 immunohistochemical analysis
Seventeen patient samples were available for p16 IHC and HPV testing. Table 2 summarizes the clinical site and stage of each patient in the cohort with tissue available, the treatment administered, the p16/ HPV status, and the clinical outcome. Two of the samples were determined to be p16-positive, whereas the remaining 15 samples were p16-negative by IHC. Figure 2 shows an example of a p16-positive and negative case. In both the p16-negative and positive cases ( (92%) tumors with a high percentage of perineural invasion (78%) and R1/R2 resections (65%). Our local failure rate was 50% and the 5-year OS rate was 62%. Although the local failure rate in our cohort was higher likely because of the higher proportion of patients with advanced disease, the OS of our patients was consistent with that reported in the literature. This was a retrospective study, as such it is subject to selection bias, which is present in all retrospective reviews. As this is a rare tumor, we were limited in the ability to perform univariate/multivariate statistical analysis because of the small sample size. This study includes patients treated over a long time period during which changes in the management of sinonasal ACC have evolved, including more advanced surgical and radiation techniques. Finally, our toxicity data is entirely taken from the patient chart and does not include physician-graded toxicity or patient-reported outcomes, which would be more ideal for this patient population.
In conclusion, sinonasal ACC generally presents at an advanced stage making treatment difficult and potentially morbid. Although surgical resection and adjuvant RT remains the therapy of choice, local failures are common and the survival at 5 years is anticipated to be 60%. Based on our results, the association of HPV with true sinonasal ACC is low.
